Related Experiment Video
Updated: Mar 29, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer
Hong Shi1, Xiaoyan Zhang2, Fei Wang3
1Department of Respiratory Medicine, Taian City Central Hospital No. 29 Longtan Road, Taian 271000, Shandong Province, China.
Objective:
Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients.
Methods:
Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. The patients were divided into chemotherapeutical group and gefitinib group and the mean follow-up was 12 months (6-39 months), the information of patients was recorded as gender, age, smoking, complications, hepatic metastasis, bone metastasis, brain metastasis and acquired chemotherapy or not. Chi-square test and t-test were performed to analyzed collection data, Log-rank was analyzed significance of survival time among groups and Cox regression was evaluated independent risk factors of survival analysis.
Results:
The survival time of chemotherapy group was significantly longer than gefitinib group; the survival time among the two groups was 29.06 and 15.23 months (P<0.05), respectively. Multivariate Cox regression analyzed that lesion's metastasis (hepatic metastasis, bone metastasis and brain metastasis) and acquired chemotherapy were independent risk factors influence on patients overall survival time; gender, age, smoking, complications had no significance influence on survival time between the two groups.
Conclusion:
Lesion's metastasis and acquired chemotherapy were independent risk factors influence on patients' overall survival time and the survival time of chemotherapy group was significantly longer than gefitinib group.
Insights
For advanced non-small cell lung cancer (NSCLC) patients resistant to gefitinib, chemotherapy showed significantly longer survival than gefitinib alone. Metastasis and prior chemotherapy were key survival factors.
Area of Science:
- Oncology
- Medical Research
Background:
- Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is used for advanced non-small cell lung cancer (NSCLC).
- Acquired resistance and severe complications limit gefitinib's effectiveness, necessitating alternative treatment strategies.
Purpose of the Study:
- To compare the efficacy of navelbine plus cisplatin chemotherapy with gefitinib monotherapy in patients with gefitinib-resistant advanced NSCLC.
- To identify factors influencing overall survival in this patient population.
Main Methods:
- A study involving 120 patients with gefitinib-resistant NSCLC was conducted.
- Patients were divided into a chemotherapy group (navelbine plus cisplatin) and a gefitinib monotherapy group.
- Survival data were analyzed using Log-rank and Cox regression, with a mean follow-up of 12 months.
Main Results:
- The chemotherapy group demonstrated significantly longer survival (29.06 months) compared to the gefitinib group (15.23 months) (P<0.05).
- Multivariate analysis identified lesion metastasis (hepatic, bone, brain) and prior chemotherapy as independent risk factors for overall survival.
- Gender, age, smoking, and complications did not significantly influence survival between the groups.
Conclusions:
- Chemotherapy with navelbine plus cisplatin offers superior survival outcomes compared to gefitinib monotherapy in gefitinib-resistant advanced NSCLC.
- Lesion metastasis and prior chemotherapy are critical independent risk factors impacting overall survival in these patients.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...